Article
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Genome medicine - 19 Apr 2017
Chalmers Zachary R, Connelly Caitlin F, Fabrizio David, Gay Laurie, Ali Siraj M, Ennis Riley, Schrock Alexa, Campbell Brittany, Shlien Adam, Chmielecki Juliann, Huang Franklin, He Yuting, Sun James, Tabori Uri, Kennedy Mark, Lieber Daniel S, Roels Steven, White Jared, Otto Geoffrey A, Ross Jeffrey S, Garraway Levi, Miller Vincent A, Stephens Phillip J, Frampton Garrett M
Abstract excerpt
BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with high TMB has not been well characterized in the majority...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.